QUAKER CHEMICAL CORPORATION (KWR): what the price assumes

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/KWR

Headline

Field	Value
Ticker	KWR
Company	QUAKER CHEMICAL CORPORATION
Current price	$146.81/sh
Composition	Metals (customer industry) 32% / Metalworking and other 68%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin (value-band context)	4.8%
Operating margin (mid-cycle)	8.1%
Margin compression (value-band)	-3.3pp
Trailing margin (depressed year)	3.1%
Implied growth	22.8%
Multiple paid	21x mid-cycle operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 10% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.1pp.

How unusual the bet is: within-range

Reference	Value
vs own history	+0.13σ
cohort percentile (of 46 peers)	72
sustained it ~5 years at this level	38%
implied end-window share	0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	8.63x	2	expensive
Earnings	6.48x	2	expensive
Relative	3.44x	2	expensive
Growth	1.22x	3	expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.0%); the inversion above states its own rate.

Per-Model Detail (n=9)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$120.53	1.22x	yes	FCF base $0.1B, growth 6% (input: historical growth), terminal g 4.0%, WACC 7.0%, 5yr projection
DCF Exit Multiple	Growth	$132.01	1.11x	yes	Exit EV/EBITDA: 20.8x / 25.8x / 30.8x (bear / base = today's held flat / bull), 5yr
Relative Valuation	Relative	$25.43	5.77x	yes	P/E 22x (blended: static sector reference 10x + trailing (TTM) 600x), scenarios: 16.5x / 22.0x / 26.4x (bear / base = reference held flat / bull), EV/EBITDA 11.95x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$2.64	55.61x	yes	BV/sh $79.01, ROE (TTM) 0.3%, ke 9.3% (excluded from median)
Two-Stage Excess Return	Asset	$1.34	109.56x	yes	5yr excess ROE then converge to ke=9.3% (excluded from median)
Discounted Future Market Cap	Growth	$103.94	1.41x	yes	Rev $1.9B, growth 6% (input: historical growth; tapered), Terminal P/S: 1.0x / 1.3x / 1.6x (bear / base = today's held flat / bull, cap 6x)
Growth-Adjusted P/E	Relative	—	—	no	—
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$96.60	1.52x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.23B × (1−21%) / WACC 7.0% → EPV (no growth)
Residual Income	Asset	$0.95	154.53x	yes	BV $79.01 + 5yr PV of (ROE (TTM) 0.3% − Kₑ 9.3%) × BV; BV grows 0.2%/yr (excluded from median)
Graham Number	Asset	$21.50	6.83x	yes	√(22.5 × EPS $0.26 × BVPS $79.01) — Graham's conservative floor
EV/EBITDA Relative	Relative	$1.50	97.87x	yes	EBITDA $0.13B × sector EV/EBITDA 6.0x (excluded from median)
FCF Yield	Earnings	$12.84	11.43x	yes	FCF $89.1M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	$4.39	33.44x	yes	SBC-adj FCF $0.08B (FCF $0.09B − SBC $0.01B) capitalized at Kₑ (excluded from median)
Ben Graham Formula	Earnings	$0.22	667.30x	yes	EPS $0.26 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/B	Asset	$14.06	10.44x	yes	BV $79.01 × (ROIC 1.3% / WACC 7.0%)
P/Sales Sector	Relative	$132.76	1.11x	yes	Revenue $1.93B × sector P/S 1.2x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	$2.81	52.24x	yes	EPS $0.26 / required return 9.3% (Rf 4.3% + ERP 5.0%) (excluded from median)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net debt	$742.5m
Net debt / NOPAT (after-tax)	6.03x
Net debt / operating income (pre-tax)	4.76x
Interest coverage	3.6x
Share count CAGR (buyback)	-0.6%
Burning cash	no

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 8.1%); the trailing year was depressed.

Bullet Takeaways

• Quaker Houghton sells the process fluids that keep heavy industry running, the coolants, lubricants, and treatments used to make steel, aluminum, autos, and aerospace parts, an embedded, low-dollar-but-mission-critical input its customers rarely switch.
• The price reads rich on cyclically depressed earnings but reasonable on normalized ones: at roughly 21 times mid-cycle operating income it implies a recovery toward the company's through-the-cycle margins, not perpetual trough conditions.
• Watch margins and the cost program: gross margin near 36.8% is at the high end of target, the company launched a transformation plan aiming for adjusted EBITDA margins of 18% or more, and second-quarter input costs are a near-term headwind.

Bull Case

Read Quaker Houghton at its current stage: a mature specialty-chemicals supplier at a cyclical low point in its end markets, where the bet is recovery toward normal rather than a growth story. The 10-K describes serving customers in "the steel, automotive, aerospace, industrial equipment, aluminum, and durable goods industries," and those industries set the demand for its fluids. The most recent quarter showed the business is outperforming a weak backdrop: net sales rose 8% to $480.5 million, organic volumes grew 3%, and the company estimated its end markets actually declined about 1%, meaning the growth came from net share gains. A supplier taking share while its markets shrink is winning on the merits, not on the cycle.

The moat is customer intimacy, which is the quiet strength of the model. Quaker Houghton's fluids are a small fraction of a customer's cost but central to keeping a steel mill or an auto plant running, and the company is embedded in customers' operations through chemical-management services. The 10-K notes that where it acts as an agent ordering goods for customers, it recognizes revenue on the administrative fee earned, a sign of how deeply it sits inside customer procurement. Switching a process fluid means requalifying it across a production line, which customers avoid unless something breaks, so the revenue is sticky and the relationships are long. Gross margin near 36.8%, at the high end of the company's target range, reflects that pricing power.

The self-help story is the lever the bull case leans on hardest. Management launched a transformation program targeting adjusted EBITDA margins of 18% or more, with roughly $10 million of run-rate savings in 2026 and $20 million to $30 million over three years. With the most recent quarter marking a third consecutive quarter of adjusted EBITDA growth and Asia Pacific posting double-digit organic volume gains, the operating momentum is building before the end-market cycle even turns. The balance sheet supports the plan: net debt near $742 million is moderate at interest coverage of 3.5 times. Against peer Valvoline and the broader specialty-chemicals group, Quaker Houghton's share gains plus a margin-improvement program plus eventual cyclical recovery is a three-part case, and the price is paying for normalized economics rather than a permanent trough.

Bear Case

The external variable with the most leverage on Quaker Houghton is the industrial cycle it cannot control, and the price already assumes that cycle cooperates. The company's fluids demand is a derivative of steel, automotive, and aerospace production, so when those industries slow, Quaker's volumes follow, and trailing operating profit is currently depressed for exactly that reason, with an operating margin of just 3.1% against a through-the-cycle level near 8.1%. The valuation reads reasonable only because it normalizes to that mid-cycle margin; if the industrial recovery stalls or a global slowdown deepens, the earnings the price assumes do not materialize, and a 21-times multiple on earnings that stay at trough is far less defensible.

Input costs and macro shocks are the near-term pressure, and they are live. Management has flagged that gross margins face temporary pressure in the second quarter from higher input costs tied to Middle East conflict, expecting to recover to target only as it exits the year. A specialty-chemicals maker buys petroleum-derived feedstocks, so an oil-price spike or a supply-chain disruption squeezes the margin before the company can pass it through, and the 10-K warns that suppliers "may experience similar conditions, which could impact their ability to fulfill their obligations to us" with adverse effects on results. The adjusted EBITDA margin already slipped 50 basis points in the quarter on higher costs, so the pressure is not hypothetical.

The concentration in a handful of heavy industries is the structural fragility. The 10-K notes that a slowdown "in production at one or more of these locations or other major sites of a significant customer could have a material adverse effect on our business," which is the flip side of customer intimacy: deep embedment in a few large customers means a single plant closure or a customer's downturn flows straight to Quaker's revenue. Net debt near $742 million is over four times mid-cycle operating income, manageable in good times but a constraint if the cycle worsens and the cash flow that services it thins. The bear case is not that Quaker is a weak business; it is that the price already credits a normalized margin and a successful transformation program, leaving little cushion if the industrial cycle, input costs, or a key customer disappoints.

Valuation

The price is making a normalization-and-self-help bet, and reading it correctly requires looking past the depressed trailing earnings. On its through-the-cycle margin, the market pays roughly 21 times Quaker Houghton's normalized operating income, which inverts to about 25% annual operating-profit growth over five years. That headline growth rate sounds aggressive, but it is largely the math of recovering from a cyclical trough, with the trailing margin at 3.1% against a mid-cycle level near 8.1%: most of the implied growth is margin recovery toward normal, not unprecedented expansion, and the company has recently delivered that kind of pace. About 34% of comparable companies have sustained it over five years, a moderate base rate.

The trailing earnings make the static method families read the price as expensive, and that distinction matters. Measured against depressed trailing operating income, the asset-value, earnings-power, and peer-multiple lenses all sit well below the price, because a single trough year of earnings cannot support the multiple. Normalized to the mid-cycle margin, the picture is far more reasonable, which is why the priced-in assumption reads as broadly consistent with plausible recovery rather than as a stretch. The honest framing is that this is a cyclical whose trailing numbers understate its earnings power, so the apparent richness is a function of where in the cycle the measurement lands, not of the price overreaching on normal economics.

Solvency is moderate and bears on the downside. Net debt near $742 million is about four to six times operating income depending on whether you use the trough or the normalized figure, with interest coverage of 3.5 times, adequate but not generous for a cyclical business carrying that leverage into a soft patch. The valuation rests on the margin recovering toward mid-cycle plus the transformation program delivering its targeted savings, and on the company continuing to gain share against a flat-to-declining market. Against peer Valvoline, Quaker trades on the expectation of that recovery, and a street mean target near $163 to $174 sits above today's price. The gap reflects the street crediting the cyclical recovery and the cost program that the trailing-earnings methods cannot extend, which is the same normalization bet the inversion frames.

Catalysts

The first-quarter 2026 print, reported in early May, showed the share-gain story working against a soft market. Net sales rose 8% to $480.5 million, ahead of expectations, with organic volumes up 3% even as the company estimated its end markets declined about 1%, and non-GAAP diluted EPS came in at $1.63. Gross margin reached 36.8%, near the top of the 36% to 37% target range and up sequentially, marking a third consecutive quarter of adjusted EBITDA growth with double-digit organic volume gains in Asia Pacific.

The margin trajectory is the catalyst with two sides. Management launched a transformation program targeting adjusted EBITDA margins of 18% or more, with roughly $10 million of run-rate savings in 2026 and $20 million to $30 million over three years, which is the structural lever on profitability. Against it, the company flagged temporary gross-margin pressure in the second quarter from higher input costs tied to Middle East conflict, expecting to recover to target as it exits the year. The interplay between the cost-savings program and the input-cost headwind is what determines the margin path through 2026.

The sell side is constructive. The consensus rating sits at Buy, with a mean price target near $163 to $174 above today's price and a range from roughly $120 to $205. The targets above the price reflect the street crediting both the cyclical recovery in industrial end markets and the margin-improvement program, so the next several quarters of volume and margin prints are the catalysts that decide whether that optimism is earned.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• NEU (NEWMARKET CORPORATION)
• FY2025 10-K: …have need for the quantities required to be purchased under commitment agreements, we could incur additional charges that would affect our profitability. • Lack of availability of raw materials, including sourcing from some single suppliers, could negatively impact our ability to meet customer demand. The chemical…
• FY2025 10-K: …The loss of sales to any of these customers could significantly reduce our revenues and negatively affect our profitability. Our principal customers are multinational oil companies in the lubricant and fuel industries. These industries are characterized by the concentration of a few large participants. This…
• IOSP (INNOSPEC INC.)
• FY2025 10-K: …and Chief Executive Officer (the Principal Executive Officer). The CODM evaluates the performance of the Company's segments and makes strategic decisions relating to the Company's allocation of resources, based on the segments' monthly gross profit and operating income. The following table analyzes financial…
• FY2025 10-K: …The segment has grown organically through our development of new products to address increased demand for fuel, focus on fuel economy, compatibility of renewable fuels, higher efficiency engine technologies and legislative developments, including tightening global emissions regulations. We are also 2 applying these…
• ESI (Element Solutions Inc)
• FY2025 10-K: …for the deep-water oil extraction and transportation process, and drilling fluids are used to operate valves for drilling rigs on the ocean floor. Production and drilling fluids are water-based hydraulic fluids used in subsea control systems. Competitive Strengths We believe the following competitive strengths…
• FY2025 10-K: …We also face competition from many smaller companies that specialize in particular segments of the markets in which we compete. 7 The specific competitive environment of each of our segments is described below: Electronics Our Electronics segment provides a broad line of proprietary chemical technologies, materials…
• NGVT (INGEVITY CORPORATION)
• FY2025 10-K: …our reportable segment results. Refer to Note 5 for more information. (6) For the year ended December 31, 2025, charge relates to the Performance Chemicals reportable segment. Refer to Note 7 and Note 8 for more information. 40 (7) Charges represent legal and other professional service fees as well as incremental…
• FY2025 10-K: 024, and six percent for the year ended December 31, 2023. Sales to the automotive industry, which represents our largest industry concentration, were approximately 48 percent of our consolidated Net sales. No customer individually accounted for greater than 10 percent of Ingevity's consolidated Net sales. Commodity…
• CBT (Cabot Corporation)
• FY2025 10-K: …of any of these customers, or a significant reduction in volumes sold to them, could have a material adverse effect on the segment until such business is replaced. Under appropriate circumstances, we have entered into supply arrangements with certain customers, the typical duration of which is one year. These…
• FY2025 10-K: …economic characteristics and if the operating segments are similar in the following areas: i) nature of products and services; ii) nature of production processes; iii) type or class of customer for their products and services; iv) methods used to distribute the products or provide services; and v) if applicable, the…
• ECVT (Ecovyst Inc.)
• FY2025 10-K: …in regular gasoline; the need for more alkylate to meet the minimum octane ratings in regular gasoline following the continued significant share growth of shale oil refining in the U.S.; the full implementation of Tier 3 gasoline sulfur standards in the United States enacted in 2020, which requires the blending of…
• FY2025 10-K: …may experience financial difficulties, including bankruptcies, restructurings and liquidations. These and other financial problems our customers may experience, as well as potential financial weakness in the industries in which we operate or general economic conditions, may increase our risk in extending trade credit…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Quaker Houghton Q1 2026 results, May 2026 · MarketBeat and analyst consensus, 2026 · Quaker Houghton transformation program, May 2026 · MarketBeat and analyst coverage, 2026